Figure S1 from Exploiting Arginine Auxotrophy with Pegylated Arginine Deiminase (ADI-PEG20) to Sensitize Pancreatic Cancer to Radiotherapy via Metabolic DysregulationPankaj Kumar Singh, Sunil Krishnan, Amit Deorukhkar et al.|Unknown|2023Cited by 0
Figure S5 from Exploiting Arginine Auxotrophy with Pegylated Arginine Deiminase (ADI-PEG20) to Sensitize Pancreatic Cancer to Radiotherapy via Metabolic DysregulationPankaj Kumar Singh, Sunil Krishnan, Bhanu Prasad Venkatesulu et al.|Unknown|2023Cited by 0
Figure S7 from Exploiting Arginine Auxotrophy with Pegylated Arginine Deiminase (ADI-PEG20) to Sensitize Pancreatic Cancer to Radiotherapy via Metabolic DysregulationPankaj Kumar Singh, Sunil Krishnan, Amit Deorukhkar et al.|Unknown|2023Cited by 0
Figure S2 from Exploiting Arginine Auxotrophy with Pegylated Arginine Deiminase (ADI-PEG20) to Sensitize Pancreatic Cancer to Radiotherapy via Metabolic DysregulationPankaj Kumar Singh, Sunil Krishnan, Amit Deorukhkar et al.|Unknown|2023Cited by 0
Data from Exploiting Arginine Auxotrophy with Pegylated Arginine Deiminase (ADI-PEG20) to Sensitize Pancreatic Cancer to Radiotherapy via Metabolic DysregulationPankaj Kumar Singh, Sunil Krishnan, Amit Deorukhkar et al.|Unknown|2023Cited by 0